Influenza Vaccine Development
$1,701,158ZIAFY2010AINIH
National Institute Of Allergy And Infectious Diseases
Investigators
Linked publications & trials
Paper 38873606Paper 38717904Paper 38670113Paper 38517951Paper 38430907Paper 37075129Paper 37075126Paper 35952670Paper 35401559Paper 35383176Paper 35115707Paper 35115706Paper 33762730Paper 33741916Paper 33658355Paper 32748788Paper 32229612Paper 32060419Paper 32034141Paper 31350180Paper 30980067Paper 30808695Paper 30715413Paper 29872070Paper 29506129Paper 29451984Paper 29263871Paper 28783708Paper 28663207Paper 26301691Paper 26078272Paper 24501410Paper 23698367Paper 22896678Paper 22449425Paper 21135852Paper 20647428Paper 20375007Paper 20352112Paper 19276436Paper 18417563Paper 17043214Paper 16011865
Abstract
Improved vaccines against influenza would enhance our ability to decrease the deleterious effects of epidemics. This study aims to develop genetic vaccination strategies against influenza. DNA and adenoviral vaccines have been developed against different strains of influenza, including the newly identified pandemic H1N1, H5N1 avian flu and seasonal flu, and testing has been conducted to determine the optimal strategies for immunization. Several DNA vaccine candidates showed promising results and testing is ongoing using DNA and DNA prime with inactivated vaccine boost. Efforts are are also being made to develop a universal vaccine strategy.
View original record on NIH RePORTER →